Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00281528 · ClinicalTrials.gov registry record · Phase 2
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
A Phase 2 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 2
- Development phase
- 208
- Enrollment target
NCT00281528 is a Phase 2 study that was terminated before completion, run by Celgene. The registered enrollment target is 208 participants.
The verdict
NCT00281528, a Phase 2 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 208 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, randomized Phase II study in previously untreated patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense ABI-007 (Abraxane) compared to 2-weekly regimen vs the standard 3-weekly infusion. All patients will also receive concurrent bevacizumab.
Interventions
- DRUG bevacizumab
- DRUG ABI-007 (Abraxane)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2006-02-01 |
| Est. Completion | 2011-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00281528
The ClinicalTrials.gov registry entry for NCT00281528 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT00281528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00281528 about?
NCT00281528 is a clinical study titled "Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer". This is a multi-center, open-label, randomized Phase II study in previously untreated patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense ABI-007 (Abraxane) compared to 2-weekly regimen vs the standard 3-weekly infusion. All patients will also re...
What is the current status of trial NCT00281528?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2006-02-01. Estimated completion is 2011-03-01.
What interventions are being tested in trial NCT00281528?
The interventions under investigation include: bevacizumab (DRUG), ABI-007 (Abraxane) (DRUG).
Who is sponsoring clinical trial NCT00281528?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.